<SUBMISSION>
<ACCESSION-NUMBER>0000950133-07-004269
<TYPE>8-K
<PUBLIC-DOCUMENT-COUNT>3
<PERIOD>20071022
<ITEMS>1.02
<ITEMS>9.01
<FILING-DATE>20071026
<DATE-OF-FILING-DATE-CHANGE>20071026
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>NOVAVAX INC
<CIK>0001000694
<ASSIGNED-SIC>2836
<IRS-NUMBER>222816046
<STATE-OF-INCORPORATION>DE
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>8-K
<ACT>34
<FILE-NUMBER>000-26770
<FILM-NUMBER>071192946
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>9920 BELWARD CAMPUS DRIVE
<CITY>ROCKVILLE
<STATE>MD
<ZIP>20850
<PHONE>240-268-2000
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>9920 BELWARD CAMPUS DRIVE
<CITY>ROCKVILLE
<STATE>MD
<ZIP>20850
</MAIL-ADDRESS>
</FILER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>w41388e8vk.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
<TITLE>e8vk</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>




<DIV align="center" style="font-size: 14pt; margin-top: 12pt"><B>UNITED STATES SECURITIES AND EXCHANGE COMMISSION</B>
</DIV>

<DIV align="center" style="font-size: 12pt"><B>WASHINGTON, DC 20549</B>
</DIV>

<DIV align="center" style="font-size: 18pt; margin-top: 12pt"><B>FORM 8-K</B>
</DIV>


<DIV align="center" style="font-size: 12pt; margin-top: 12pt"><B>CURRENT REPORT</B>
</DIV>


<DIV align="center" style="font-size: 12pt; margin-top: 12pt"><B>PURSUANT TO SECTION 13 OR 15(d) OF THE<BR>
SECURITIES EXCHANGE ACT OF 1934</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>Date of Report (Date of earliest event reported): October&nbsp;22, 2007</B></DIV>

<DIV align="center" style="font-size: 24pt; margin-top: 12pt"><B><FONT style="border-bottom: 1px solid #000000">NOVAVAX, INC.</FONT></B>
</DIV>

<DIV align="center" style="font-size: 10pt"><B>(Exact name of Registrant as specified in its charter)</B></DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><B>Delaware<BR>
(State or other jurisdiction of incorporation or organization)</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>0-26770<BR>
(Commission File Number)</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>22-2816046<BR>
(I.R.S. Employer Identification No.)</B></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="47%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><B>9920 Belward Campus Drive <BR>
Rockville, Maryland<BR>
(Address of principal executive offices)</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>20850<BR>
(Zip Code)</B></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="7%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="88%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="left" valign="top"><B><FONT style="white-space: nowrap">Registrant&#146;s telephone number, including area code:&nbsp;&nbsp;&nbsp;</FONT></B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>(240)&nbsp;268-2000</B></DIV></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>Not applicable<BR>
Former name or former address, if changed since last report.)</B></DIV>

<!-- &nbsp; -->
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><b>Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions:</b>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><b><FONT face="Wingdings">&#111;</FONT></b></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><b>Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)</b></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><b><FONT face="Wingdings">&#111;</FONT></b></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><b>Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)</b></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><b><FONT face="Wingdings">&#111;</FONT></b></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><b>Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))</b></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><b><FONT face="Wingdings">&#111;</FONT></b></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><b>Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))</b></TD>
</TR>

</TABLE>
</DIV>


<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>





<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">








<DIV align="left" style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"><B>Item&nbsp;1.02</B></TD>
    <TD>&nbsp;</TD>
    <TD><B>Termination of a Material Definitive Agreement</B></TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">
On October 22, 2007, Novavax, Inc. (&#147;Novavax&#148;) and Allergen, Inc. (&#147;Allergen&#148;), successor in interest to Esprit
Pharma, Inc. entered into an agreement (the &#147;ESTRASORB Termination Agreement&#148;) to terminate the Supply Agreement dated as
of October&nbsp;18, 2005, as amended, related to the supply of ESTRASORB by Novavax to Allergen (the &#147;ESTRASORB Agreement&#148;)
effective October&nbsp;22, 2007.  Pursuant to the ESTRASORB Agreement, Novavax manufactured and supplied
ESTRASORB to Esprit.  In a license agreement that is not being terminated, Esprit was granted an exclusive license to
sell ESTRASORB in North America.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">
Also on October 22, 2007, Novavax and Allergen entered into an agreement (the &#147;Testosterone Termination Agreement&#148;
and together with the ESTRASORB Termination Agreement, the &#147;Termination Agreements&#148;) to terminate the License and
Development Agreement dated May&nbsp;9, 2006 and the Supply Agreement dated May&nbsp;9, 2006, each related to the development
and potential supply of a testosterone product for use in women&#146;s health (collectively, the &#147;Testosterone Agreements&#148;)
effective October&nbsp;22, 2007.  The Testosterone Agreements called for Novavax to co-develop, supply and commercialize
its micellar nanoparticle testosterone medicine for the treatment of female hypoactive sexual desire disorder.  Esprit was
granted exclusive rights to market the product in North America.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">
Based on discussions between Novavax and Allergen, the parties decided to mutually terminate the ESTRASORB Agreement and the
Testosterone Agreements.  The termination of these agreements is in line with Novavax&#146;s corporate policy to focus on
its vaccine business.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">
Pursuant to the ESTRASORB Termination Agreements, all rights and obligations of the parties terminate on the effective date,
except for obligations related to confidentiality and indemnification.  In addition, Novavax has agreed to ship all product
on hand to Allergen and provide Allergen, at Allergen&#146;s request, with the access and information necessary for a third party
to manufacture ESTRASORB for three months following the effective date.  Allergen has agreed to pay approximately
$1.29 million to Novavax, primarily related to inventory on hand and certain other wind down costs.  Allergen will also pay
any additional direct out-of-pocket costs incurred by Novavax resulting from the termination of the ESTRASORB Agreement
that is the direct result of Food and Drug Administration (the &#147;FDA&#148;) regulatory requirements in an amount not to
exceed $100,000.  Novavax has agreed to use its best efforts to return raw packaging material and will split any amounts received
equally with Allergen.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">
Pursuant to the Testosterone Termination Agreement, all rights and obligations of the parties terminate on the effective
date, except for obligations related to confidentiality and indemnification.  All licenses granted to Esprit ceased
and all licensed rights revert back to Novavax.  Finally, both parties agreed to release any claims that has arisen or may
arise under the Testosterone Agreements.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">
On October 25, 2007, Novavax issued a press release announcing the Termination Agreements.  A copy of the press release
is attached hereto as Exhibit&nbsp;99.1 and is incorporated herein by reference.
</DIV>

<DIV align="left" style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"><B>Item&nbsp;9.01.</B></TD>
    <TD>&nbsp;</TD>
    <TD><B>Financial Statements and Exhibits.</B></TD>
</TR>
</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">(d)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Exhibits</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">99.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Press Release issued by Novavax, Inc. dated October&nbsp;25, 2007</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>SIGNATURES</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused
this report to be signed on its behalf by the undersigned, thereunto duly authorized.
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Novavax, Inc. <BR>
(Registrant) <BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">October 26, 2007&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Len Stigliano
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">Len Stigliano                                      &nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">Vice President, Chief Financial Officer, and
Treasurer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>


<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>w41388exv99w1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
<TITLE>exv99w1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;99.1</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><IMG src="w41388w4138802.gif" alt="(NOVAVAX LOGO)">
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="5%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="93%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Contact:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Tricia Richardson</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Novavax, Inc.</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">240-268-2031</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>NOVAVAX AND ALLERGAN TERMINATE<BR>
MANUFACTURING SUPPLY AGREEMENT FOR ESTRASORB</B><BR>
<B><I>Action allows Novavax to focus on its vaccine business and reduce cash burn</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Rockville, MD </B>- (October&nbsp;25, 2007) &#151;Novavax, Inc. (Nasdaq: NVAX) announced today that it has
agreed with Allergan, Inc. to terminate its manufacturing supply agreement for Estrasorb.
Estrasorb was previously licensed by Novavax to Esprit Pharma, Inc. (recently acquired by Allergan,
Inc.) in 2006 and is an approved estrogen product for relief of moderate to severe vasomotor
symptoms (hot flashes) associated with menopause. Under the termination agreement, Novavax will
complete the manufacture of remaining orders for the product and plans to close its Philadelphia
manufacturing facility over the next few months. Allergan will continue to sell Estrasorb for the
foreseeable future from available inventory.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The goal to exit manufacturing of Estrasorb had been a high priority of the Company&#146;s Board and
management team since this activity was not strategic to the Company&#146;s core vaccine business and
was a cash drain to Novavax. The Company had continued manufacturing Estrasorb since it was tied
to the product&#146;s license agreement. Additionally, Allergan will return to Novavax the rights to
develop ESP 210, an investigational drug in Phase II development for the treatment of hypoactive
sexual desire disorder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&#147;We are focused on executing our vaccine business strategy and have previously stated that one of
our highest corporate priorities is to divest the Company&#146;s various non-vaccine product candidates
and technologies. Today&#146;s announcement terminating the Estrasorb supply agreement is in line with
this corporate priority and will reallocate our cash to our core business, the development of new
vaccines,&#148; said Dr.&nbsp;Rahul Singhvi, Novavax&#146;s President and CEO.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>About Novavax</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Novavax Inc. is committed to leading the global fight against infectious disease by creating novel,
highly potent vaccines that are safer and more effective than current preventive options. Using the
company&#146;s proprietary virus-like particle (VLP)&nbsp;and Novasome<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> adjuvant technologies, Novavax is
developing vaccines to protect against H5N1 pandemic influenza, seasonal flu and other viral
diseases. Novavax&#146;s particulate vaccines closely match disease-causing viruses while lacking the
genetic material to cause disease, which provides potential for greater immune protection at lower
doses than current vaccines. With an exclusive portable manufacturing system that allows for rapid
mass-production of vaccines, Novavax is uniquely positioned to meet global public health needs.
Additional information about Novavax is available at <u>www.novavax.com</u> and in the company&#146;s various filings with the Securities and Exchange
Commission.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Forward-Looking Statements</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>Statements herein relating to future financial or business performance, conditions or strategies
and other financial and business matters, including expectations regarding product sales, operating
expenses, and clinical developments are forward-looking statements within the meaning of the
Private Securities Litigation Reform Act. Novavax cautions that these forward-looking statements
are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that
may cause actual results to differ materially from the results discussed in the forward-looking
statements or historical experience include risks and uncertainties, including the failure by
Novavax to secure and maintain relationships with collaborators; risks relating to the early stage
of Novavax&#146;s product candidates under development; uncertainties relating to clinical trials; risks
relating to the commercialization, if any, of Novavax&#146;s proposed product candidates; dependence on
the efforts of third parties; dependence on intellectual property; competition for clinical
resources and patient enrollment from drug candidates in development by other companies with
greater resources and visibility, and risks that we may lack the financial resources and access to
capital to fund our operations. Further information on the factors and risks that could affect
Novavax&#146;s business, financial conditions and results of operations, is contained in Novavax&#146;s
filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov. These
forward-looking statements speak only as of the date of this press release, and Novavax assumes no
duty to update forward-looking statements</I>.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"># # # # #
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio --><!-- /Folio -->
</DIV>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>w41388w4138802.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 w41388w4138802.gif
M1TE&.#EA60$W`/<``````(````"``("`````@(``@`"`@,#`P,#<P*;*\`,]
M>`!"<P)`>@!"A`1'?@-(AP@Y<P@Y>PA`=@E$?0=#@0A"C`I(?0I)@PI+B@M/
MA`M/BPA2E!!$=@Y$?`]%@A!(?0]*A!!,BA!*E!)/>Q-0AA)0BA%0D19*?!=-
MA1=-BA5/AQ5/B1A2E!A:E"-.?A]-@QY/?2!2A2%4B2%2E"18AR-7BQ]:DB=4
MA2A5BBA5DBE8ABE9BRE:DBU?D"ECE#!;AC!;C#%;DC5AAC%ACC)ADC!CG#%K
ME#%KG#E:C#EBCCEDDSEEF3IIE3IJFD!EE$5GF41HAT!HCT!JE4%LFD)PF45R
MHD)SK4AME4EMGDIOH4MSETMRG4ISHTYXF%!TEE)TG%)UHE-YGE1ZHU)[K5AW
MG5IWIEM]GEI\HUY]JUR!IEN$JV!]HV!^JF*#I6.$JV:)IV6*K&.,O6Q\K&B`
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M_?G]^?K]_?WZ^?WZ_?W]^?W]_0``````````````````````````````````
M`````````````````````````````````````````/[[\Z"@I("`@/\```#_
M`/__````__\`_P#______R'Y!```````+`````!9`3<`AP```(````"``("`
M````@(``@`"`@,#`P,#<P*;*\`,]>`!"<P)`>@!"A`1'?@-(AP@Y<P@Y>PA`
M=@E$?0=#@0A"C`I(?0I)@PI+B@M/A`M/BPA2E!!$=@Y$?`]%@A!(?0]*A!!,
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MJF*#I6.$JV:)IV6*K&.,O6Q\K&B`GVN&IVJ%K&F'M&N$O6F*IVN*KFR,M&N4
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M_^[U\_'U^/'X_.____7Q^?GY^?GZ_?G]^?K]_?WZ^?WZ_?W]^?W]_0``````
M````````````````````````````````````````````````````````````
M`````````/[[\Z"@I("`@/\```#_`/__````__\`_P#______PC^`,6)HT:P
MH,&#V[K9"P=.7#B!$,5Y<^B-F[:#!:%M`]<PHD>)X;Y]VP:1&S%7EP2):<)C
MA8J7*FP4X:)'$JI?U`2&VPG.F[>''KUMFT8M6C2,1ZE=$_JQ*42>0KDAE69-
MVE&G.C=^LP8-(\9MW+AUC+C36[=KT(AZ+3ARHD2L3;MUV[:6X+2$.\G:ZR:4
M)#6U=1-N##J1&C2CB+U&,\NPZ<[&W,+1K5N4&DFXXHAHWLQY\Q`@>;;Q=/CQ
MI[V!<X!TUBRDE;BQ6'\*I-:*D!0:("[H!A'"I0H2P$&`L##A0XPD>48ITZDS
M+UE0JH<,Z3P=B")PWS![!/I05I+52:K^@\+<#1RW-SNFK]X,Q!)(H!$YBM,F
M)\AZS['$<9OH5KM`LXH`\=UZ3@SCU&,D*;.%=-*M)MT7SC06D5O&?,'#$$*$
MUR!G29@23C?:[41-&_;=!P04N<"'E7`LMNCB!2"X1I9CX40S!04MZG9!!ZF0
MYE\RDDR!P@06@("""B7`!!-P),"$@G`=%#=$(+E`]).*`A%3`XXN"G>!!4`H
M@Z5_XHB4!Y<L>N#!!13@<`QF$[&"PFY=LDA!F(]]Q-$WX6!"`8QU@D!!'ASU
M1Z9`RNQ@@6X8N,C`&=CX-*9#V4G2@9=TLJB;!Y<P->%.W:0RYP<?9&HG$`9V
M,V9'LED*Z(O^#TQ@B3>P.:7DK2^MD"0)($BQF%@^$D;-%B#<6D()**CBW$?;
M7#9-)$D06:P*NOJ&:ZZZ*JDK"!/(X(>!0F47T7Y^7&`M3"G\AD(HRY(Y4:+3
M&FM!()B%I`T8\5[[4@H@,(+5ASLQHT2^MX(PQ'*'>N0)","M<.Z1^3F$93@3
M?>-,$O&>^Q()*Z#@!#1C[I3=)@R3D"2N*UP`!C5S.267.++$`,+)MY)PP2&'
MZ@O3L;^5X$$DC+WV45[#$NQPLN*`V)1HXM!RQ03FIF#M"DSJR^0*4A]K<@G<
M`K$)-T(_1=(M,F#0I))2K^`!&Y<E/%$G,]>L0@@QW%)O.*B4K/'^K2GOL%Q/
MI763'2,$*\EU*%8FS$T9(+@DM9(@;'%-0[*1Y18E&9>@L>8I='#)I.955,@'
MQ_*L)'`_5S3TA]TL\\0$*)@.>1LY50X7D[CC?K+)(=S@2UZU2AQ.T;FK@`+2
MJT/420P6E-!DZ>GV_)+69\-4+=5G.ZP"C']0(UE#CPEUAKG%.P_"#K]\>&AV
MVXA1,NXO@7!&VT^])1`VQ&YM\O/.5VVSOX`+2DC$X0O<_&9_3"K!!=H@FDD-
MK2.^D`%PIJ>_#W0B:3XQU&LF`@TB3*MT_3M9Z4"@A&A\3V+_D0LUSF`!:N5N
M@D=R1=*RPYT/><,/$^"8R39F/BG\+5C^6-&9OD#@ALM,JC#$XIOQ5!$7DH!#
M$B=HG+:2="39J8!A#',>M;2GKQ)\H`T@`UOXQ($*%(3@6L?Z@"4^%#S'9$<7
M,J`9MDCP`53H9SL2`18J3A`[A^W0A;C2P`Z,(2&LO.$"TY,C"3*`/A3"157@
M(`GA3.:P).GJ`DF($/WBLPUO3,)(#@MEDGBF*R9]8!.2H>&8E"&%"TS0</%+
MPG*^`0Y0B40<H3A!]0QW/E^(8Y-P$>*U>&7'V`PDB=I:HF,:HHD/%&X%)K#D
MD7)#@0E0X)H3F(`#+M";`P[1`FU8BEM\(@X;%0Y)O)+<+?T#MD5(T7`*E`(U
M1N*4[%#C"A_^B)WF-`<_7'U@$?YQ!=<`>;H/7,*1CZPE-*0P,\T=S606`&BS
MW"@.96#,H:(\V[&L]8$DF%!<'P&1+G9@+KF1H',,_,:5L"..8?S`:'Y4`1,G
M2B9AXDJ!'RODA(YI-&5^)#NQB`$&-'<ZHB()!!W8@1@$00E/A"(4EU"$&8;P
M`=A1C6]:]*(DY-(328FC$@S;W!574`OY:,<GT(C".W>FP$F426D_Q:61D'0N
MX>R-:D`@AG:HP84/XNH"6TB(!IOBEE8\::-80P%P:.#+?YWFD]<+):^.A*04
MI.M(%N`$!N,"HE3P:V.YFF`*U(A"L%W##&O-%;]`4`G2`#.(-H7^YP<.X:F@
M\%2)R/N(,YPP5'U-\P-2H,0O7KL-983B#"#XP$VC^1*ZS4(B&=Q),H!0N)-=
M`!%):Q=AQ2$GS5$6)N=[$\6VXY-O3$,*&*"6457P@3,,C&\N^8"_X-*0A2E6
MCBZLVR_/JI\\-"Z4VDL9'0:['65XD*ZBC$$=SG6T%6A@"HLAL/K$,0EG_F9?
MSG-)!FY@-^A2V`/K=9(%!+&-=>8LMJ<C00Q2M-VBX9:)36$$Z808`A0LPAG-
MV<M<1.,6;GA"!P3;Z/14=HV\/"8<@CAG_)@`#;DX4&QUF!G6;O6!/Y"F5N,5
M!]Q<(L=B^8(2B#2<PT#P`P/!)1S.&)C^%77%-8#"]4`".<80_AM*:EE6%O[Y
MI/5""8(O/*,*B`0.4;>U"9"XK!O<^`.,?(,]WUB@"=&`""UD5N<E6>`,.0%+
MPL1QTR;QZXQ(LN1++C`_&T[D(4CL:6Y_DAUX[9*M)$#!)ZS$&/YD,"*YN*@5
M$PD".[;M(;F(00H<6K,8(?0I5YK(,*B;+2Y?V&X$CF0XH,&$,'?9#15E=J@Q
M.ML9!F^`A-/BDI($`B?D!#-\$@?)MJ@]CH%@96^6F$_`9M%I^;$$*3@!XC#Q
MOD'SRU=).Q!)HA&&"=1L=QZP<HVDH%R'EFY[3"A&F9X,6^LY#P4I(,+Q3+>[
M#R!N+J=^BXO^D[EJP8G#4KO>V07<VD8XRT(&&="9`LTPF(ATXPR]V:?A+N`'
M>6]GC)>8ZRA##0(Q=#+:8".9N#<&@AC00B"%\$`(1@G@\QG(K!XAR2^`O,N&
MD0`&,H(+G[;QA3`7>];Q+@LY(_$!CH4660"O-Q<3:<&)8Z8822BIW)XT"G$(
MH@,;#^$*0*"#IX-OTYS&ZN`-L8:&JM<EO)+E`$F3ZA=;254V0F3*GR2&(C--
M.S1MA`6:=-<2Q*`734D%"%+PZO@=C"("!,HVMN!*CF7KJ*BPH6/$<;&9O5I^
MD2&@#*:.K4I^H!!A"PK8O-$&):O``CWW3[!;?T4B1"C>.FGUG$/^O3%>=0IL
MDOC`[7EX`2E`(]V8H44-]'ZZ[0V!$3$XGGJ?IP$4F$(_E$/\M;85"5_<H)M(
M8CPF<P&%D!>R47DDQT2L(@ZZD"TIUW1XIBH4-S2]1WU'=5`?00U3H&1/0@J_
MI$%7`C:W$`,\,VPG@P%,X#U\L31?E45R=#RN84-Y8'8`-G@[H%=.X1:T<`)6
M<P%`@&.O)1`DH0AQ<RM/XB\3%A25<@&C1#,@$`3*X!8NE5IL!@+L$B*X]"0U
MLS7"`6JDMT\7\`AE,7F;=BVL=P$`=0AM1T'J97H==H"WE8"OD7]!QX8%(SG'
MYA\[$75+QU87D`9@\Q%@14E_E08E!H+^E"(.HX-8?P0"DN!S0Z,,0Z!Y=?4%
M1B0.M[`S-;@]R*==XX),VD("(0`"?1>$#A$-3N!XD!,#!G)$[S($Z<5F3-(O
MP>('#*,M+@$"$*:'XB!C^]<_HK0O(6`!>,!CK(9XB8>+VX,SRJ`$UC8]HR8&
M.:$J(@>*N:),\C$1_B5$'^`(!.8?)`$+Z'13@U="/Z<,0)`!(<9F.#`,X1"(
M>A(-2<"#,=4D*.`W.D&-'_$(KK1%&H4"H]`8.\$-[H-@D@4"->".$_,0#1$*
M]C8]+C%XAO@OX<`*)HA?"W1EI3$1_)A(V$,"-Q@.IS$1N.!-UQ@_B`-$$^(6
MV-`&I.,;^*;^6%]H.BGC!=,@&7SQC=HQ3-N#"`\A"HH%2RK`+Q>4$-6H:@H(
M/M=@C36(+*X!(A,X-!4U9_A%5`CY"]N1'8+0/%CE?9+Q<Q-11G-T0!_@!_"X
MDN]"72+T/"!P!3<9B-F1"LVE,2E3"%C7'$+3>Z%V>X-W`^[X#?I80V[`A-)C
M5#(R*6`S70^9*Q<0"+4$(MC1/H3)?25@`FVI#8#Y&B"5=;Q'>\AR8;BH12]`
M0F;FB0G#DR"`7=Z`#>/S:E@#`DF0#%^)@-:C3""EEWLF2CO@2Q*X:0\A#?E3
M,[GH=(3!@#(S1&%09`(D$2[Y:B5P1K?PC>.U".*W7B8#`N/1-B+^L92J:#V]
M8V9D\1#<0!*1D$5;!#D'E83P80PZ0%1_Q#620S%C\@WMI%P,%@(RH`M)`YG9
MH0H-17IMJ&\!IY-?N6RK!YK[!X%E@8P>@9K811+!1C"4!`)_8(!Q6)M(DQT3
M80S4A8M\]GJF62\2D09%N"0;@P+%1&OZ<0;*Q9,=ME,M=0//%`+S@WT"P2?#
M0%*VIU&]$FD1<4L.V8?&1PC)<T?#H`,3-'=7M`7>8S\1<0EM)S7O"0*HI%)-
MP2?H:)[60P%U8!;4B!W=0`U4,%1GDP*4%3GBI)/-(AJQL`/9DZ`K@#A[H9,G
M)C>IZ2.*T`%=ISF]$3&T>8U(@VHMM0/^^5*#)(1C40D7,_AJ_YBBB4-&/)A,
M2'(!\S4A#6$)+UDP('!_^N@1?%((9*HUN0("&/AST_!>H0D"-("512H.=#!Z
MYVFBN/`:^A@6W#F4SG."![.@JT,X)AD_*O!T#\&0``,W'',DED5!/>)59R8.
M>A!6QJ(U11<9*F4[#.J@_R$.SX`Q2J1`>/BGU*),"RH,."!'ABH%$2*HR+BH
M<E-9CLH<Y70%^>)0O.($/@H1V<&=2@IQT<!23C$,-;`[#6-&2H`P,'IRXI=B
MURD(-"(QL3"4O_H;E/H:SB&"<\-EC0A0H.(4Q0`$1_)J%V`&V)!\#@$B:89(
M,&E)&,"D68;^&;"P`QCGFL/&*S'0=Q1#*PP*$=BZH*80E'.71H4&KBZ!-/PQ
MJ/A5=4J0KN2$C'0PF=8C:"G0(^%Y1U#*91%)-4;B&JHD&K2PEZ<#`FYE8A#Q
M,H6@=X+W,P&WD@YA8"&@/Q/TG#>`E2IB9&>!+U4#.;O()ZC&#87P7P%HC[[S
M'@+15>KC3KZQ-1US`G8$+,CV$^4)L=RW`C5F1RN(1T(S#)/(0P"F)$^R`U5"
M,2U7I^UWI\"C#69@`2C`9DL"`D!@#*]QJW)(3N$@B<['NNZX'XG*+(V'7S/;
M)&&'E_MA#"_5,*=S`7H0$H\I%WU+;.#5NL/*+`1T`]^UND!P#$G^^!_'B`B:
M=S*B!`*!8!9M!#8.>;<[@P*NP1&/T8P22D=M<):#ZZ7A,(7N.3T@H`6U0UCQ
MFP-G=+1H6EO_,9#B``U@X`$?BU@Z9SWE)R9WB8P[*YX,B!N5=D`@X`>U-'(8
MRD0K.&T,I3--EPL9C(S0L(&XTKLR4"5X%!;>0`@Y9'NKNZM&5F\G53`*A[-D
M828M="T@$`EYZ!'%\%)&574WH)\;:W/=H+Y7=2L\]X&D00I!"4_FZZ1D`2*+
M<"D\0T7"X8':L96O5+XHX(&;Z2/A<`UY`'@?VWW41P(38(@M>ZVXTB2DZ\#B
ML`BHBT8J@&?38(WA&JC#>@UAX'R\$@K^2[MI8%,,//!,[H8J6-$0OA`#&7!2
MU@(<Z^*DHG"+T7-`Q+G&-RH.$7K$W;<#M.`,R:`,SC#*HZP,IGS*S?=PAFIE
M^^D1+_,(<X4K(7`PLLL-:E`X_&*3E8N7?&(,0;"_5#<W2^`+SB#*I'S,INP,
MJ1`#="5F@%5B'A$Z)R<<)OI=TXLM$VNCI]G&5X1=3_$0SJ!6G#QD64`-UI`%
M2.E(WM"W0@0"@C`1H9O(XD`*;8LRU-*6]PH1L,$-;8!(E0P3"X2[^H$&_1@]
MP=%Y`OD1W``'Q?)'N=(;G,$@#<(@1)`$,/O#55<#^ODRGR(.OR"C:!3);O$+
M;HHR(%"40W/^:HQ@-J'V2B60`Q(=TQ2M&1WS.!9W/%(;'PVA"H.WA4\BDT:(
M)"'0=SDK$-C:'%^9-_C5,QY0"=?05Y:W+./+P4H`,O'L%#W!T*WG&QZ@!X,E
M'WFA"I8USK^A`^#I"S@@:%QTQ2>$?279T,[)-5WX(L+Q`:-8+#0)8'24!XG\
M(=N(BR1@`8`H&Q6VQ1M#!&(BMMEJ#(7<?>+VG(%2)\#QS]?89YN4';X`!('V
M2I`<!(5,?0JD`[-:U$==/Y'4SXQZ13N@"U^0SA9ZI#SCT-.#`N,A$ARQP)?'
M$(I<`PT=TIYP5M>PP8Q*6@T!"1Y05(/G*PR)0MCQCOTL.P"&6#7^F#7[M$];
M(]VA1#>H]\7-00N*-6SH0C4)^2'4@`6];6GS-29N@0BW>&&45#I8$TICK=?;
M=K@-PV5/;$-\X@SR.H['DKJQ)@NA,`*QQFBKZT.4IW_<?*?13!*+W%.\P@9X
M/+0P!A'-8@9,V#^X`INSA&J[K*)OL0V#:8'/V;J@%PXDL]4@T`6B84[&PT.\
M\HAX)&VT``,/EYLUF..;*)2X^`&$$C)RL0U]-7Y90ZK=$7\;SHJ"^Q0@0@R$
M:M/[I^-2SD5W>RR6S3IAW`8=8.`B-+'@4"ZXRL+3TP'A%**84=I$+`Z/X`$,
MMC%2:GD101*FT%"4?6$@D`;7@+W,JJ+^'7$)0'W-)H,!?D"&]32[/5"BB;1B
MXM`*+W#-SH./T>P0V\":?*36@J;A**9$.'QZCL$80?J9?C1X6D`2?X#7NT1$
MW/#AV:>(6MJNF>XDE'4U*3"*K1`2%..+\#1J+`L.SR#"DWTN)4`!BY`G9;C@
MWKP=<H&*6(15NT;A34$-3C!U^^I=()`'/LHGBLT-W[`0X'`)E+;4/2,#MT#H
M%"4([,=KV&6+2^(;%/K5C"$+QE/`E?1"]$[O+W$D^[HQ/JY!'OX-T>",GZE%
M3Q(#OM!!Q<)<+F2^IN:I\4NHNU;O$%\\YY(UP($!\Y,=H:"%ZL5]O209$T$V
M#0WEU*(!*T#^N=I<<:-[[.%)$F74WI"';^,'J!7N$:/0HB'VWX*B!:U`$KSZ
M$;_@7QE@6<1[.M#7$"?O$1&J1"#0!+^P?0?$3R\P[GIB%MLP/L$\94.23=>T
M]5S?]=5D3=<$@$X<`T(<']YP2Y)0A(^=PZ-PB[*#I@,T6.O<<*\6`FSB]7CO
M]1-PW+Y!W4B"`GA&"S(@1:H+R2=0:"*A-'[>T'L3`CM@-T??%&A>/WUQRY!7
M2I_IFC[U$=>0!@U72HB+-0JD`F<`"L-`#?#H#=>@#*J0!SM``0Z-T>XG<:E.
MIZ?6#8T7J\?3)&D`F@E$HX=8&HMN1KGZ\BOP`F>@!WFP_,S?_,[^__P_$*E%
MQ5YXH$$-`0X@DJ-NKU$AX`1;4#UNQRN9D#3YYZ1.#M?V[0)N\/SLS_YZ4`64
M=<0=<T5I,`S5YCBZDKI)8@%YD.HFYQ``<<T."!4D2!14L4(%"A47I"@3%S&B
M-XD5+:K`F!$A"$06/8K3I8,@"84'-6I4B$+51V[BAB6Y4&+%P14E2F!46$+#
MA0XWI)RIXR>/&BH[0%``85,ASHPK4!!<*2Y<MX\6IX93E2+A38TD0)C4"`($
M*JD4*W;S=HT,08PR"ZX`L85:5;H6)9U`87`K214@8MP2!\ZL17!Y+APL`;;$
MTZZ)00QQYM&;-V[AQ!6*J;!F6PMAL-7^!?W+*`J;3!>N:`)BQ>K5;DM<2`+1
M8DME2;X:E,FZ)H4VURB#$S>8[DF,!SF"COBH0UOB)U-&M;CMF[A;.RY@1+'4
M>8JG%BQ,F$!!?-+<VC.6!H&BDKAMDX5_!!>.(C4LY!ER14@<!)-HP:E6M`R5
M$_32J(3T0A%G.N0`G*B8(4BC"3\5/J"CI8@LLXB6@MSJ"JRV2+"@HX_"V<8E
MD393@2L44$@E00P7M`B.ZU;3CR"&='-,!5<2M,B;$C4<*2'M2@BA`T<HL@PX
MT)HS3L2ZPH%&"H(D;.ZYC[KIID19@)@@N\2(J\D@,0U:(07=:$3)I@M.F"0^
M"Y$#!ZUOPMG^Q+X4FPM+DHD\"H>:+6*B\C4LJ`E'01C#"0><.,59!`032(`P
MK!AH"6Q.B[JY1HRDM,(S(X-D\(7/0JG";*L-5XN+T/A>A'$Z6F*`E"&-9%U(
M2*6\8B0X0R="5)Q)KL.)QM)"4`'!;A1%CLF^G*1KSE1H[32AA:#K43YQ>,&B
M@Y@(/(D$FV@*]LR3$IO@!U"\D<\;2T'[9K(YE1DB*>8Z!0&(8:0*SJ-1R*/2
M*T[PA?'"_Z@:9H<02NKV`C?0+?%2<4(1"UH\O6JC/:LL"V<8'C1(Z"!O\P(A
ME$2E8G7!;[:YYHP/H@U7*0^^('1$1,.Y)HT.9/56J8(P``*P=>O^4O8XT+8)
MAYLZ5F;92H^`P[*;<)PI)(:;\107)=V:.NJ$,WIA#RUTE:Q+L`1)]2#":$'X
M8[)"P8Z(&BHN0#,L)YX1Y[^`IT(7+7$$@=N\C`@";#+"P(F&B?18_KB5J223
MJM0[F0)!"FC\VS/@D\5194`//7U+MWI#)?EB%X]1@BTQ2\/H@BF4(1&Y,7'S
M%@-FJ]+;%Z->QWV%$%0"6**1FX[HEC9BH.`"MK!#(04SQ42H)IN>OV""$[8@
MI:632X9Q45]D".'YUY_7_:^ZDY1H.D\^($&K,0OZX)+@WKL[7UVX)_;UA2QH
M@QMNWD/VD:1PQUT(Y((ECSBM8,3*#TG^2'`!][FG<@&;SY\2`\#3F<E`GA!'
M2WH%((H031RN>`%#P#+""[!!&][X#W#@)QX6BJ<#$V``(79%EZE,H@,MQ*%X
MP-.!%F&O(H++("T$08033.`#(`A!",RD$+&81"Q/O(`#++"#-J#B&@%##HG:
MP``*@">'7:0``\0@G89)1#K.&(($PI/#"0"!=4S#XD>PT0;PK+&%X.%`*P)3
MK8S=X(LXG``'0+''V9R,#@KXH@<HX$9DQ5$B:A.')^SXQSI.0`)Y@!]H&+&<
M3I7``XQ`(454Z)$_E-*4?Q`*'%#!MJI,IAO1,,0I95E*/>0A#[THU).:AJ%H
MM.(06]@!"C[^$)X+7("%QA2/!U"`@RGH(13&,%09'0F@;MS"#WK0PRS]L$T_
M](%2THQ(B8+1!S_\`9O9-&4=3N$CX/CP;N'(13G1>4ILVB$4W)CAS+9QB3S,
M4I9Y($1D6!*.:2C"#OZL92BR-$T`(2H:A?#G*8522T+(!IQUR53?FF,@%(PB
M7^X$#2OY)!6[+<@;C:1AH6:X#6?<`A66*$0>X-"&,[3!#7D0!"-"$8MC7/%"
M*&5H=$`Z4MIE\5A!K<@,6_F-?*8+B^TDC-Y:.1&G(=4R0$0J:`@VA(-MU"L[
MT$5P-@C!+%YHJ!Q$5T@5I220JO1GA)E()K.:K[GJ,E$BC2.K2NK^._E4]8=C
MS:*B`!L1O2UNI')]Y\BP>-:Z".AXQ4G13"('$<2*2JR@$24*D>.T=)T5;-AS
MY<Q(UBO*F)6Q#$445F5VVL#@]6MX7:S@4.C#SO:HM=9B%R2K195V+4V%@XWC
M2954V?=YPQZX#9B2"/$!"86))KSQZ:%8^TCBCO9""Q)M[WKD'M6:M:XR^RYV
MP^N[H+*VNT1MY73'J][K3B8:7B`/:R:XE0XL0KOCQ6]^];M?_O;7O__5+X9*
M9#OF<@@EQ!K%R*H+8`8WV,$/AG"$UQO.EH2"-+D9UVMV<(NB[57"'P9QB$4\
M8@!OL%!_L(!7J+0AU;'GHB2&<8QE/&-:&F_0:<[0`M(VNH()[$BI-`9RD(4\
MY/SV"E$MT851NI6SQ1!A&.PE<I2E/&4J1Z03*XK6!+X@C2IWV<M?)O)5O:&'
:$&Q.(RGH0"'`O&8VM]G-;X9SG.7LWX```#L_
`
end
</TEXT>
</DOCUMENT>
</SUBMISSION>
